Cognito Therapeutics, a clinical-stage company developing a new class of disease-modifying digital therapeutics targeting neuronal pathophysiology to treat neurodegenerative disorders, today announced the acceptance of six research abstracts at the Alzheimer’s Association International Conference^® 2021 (AAIC^®). The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in Denver, Colorado, July 26-30, 2021.

“Our clinical team continues to produce compelling patient data of both physiological and symptomatic improvements that support disease modification for our lead digital therapeutic development program in mild cognitive impairment (MCI) and Alzheimer’s Disease,” said Brent Vaughan, Chief Executive Officer, Cognito Therapeutics. “With several significant milestones already accomplished including Breakthrough Designation awarded by the FDA and our Phase 2 data showing improvements in memory and cognition as well reduction of Alzheimer’s-related brain atrophy versus placebo, we are looking forward to sharing our latest findings with the international Alzheimer’s research community at AAIC.”

Details of the presentations are as follows:

Poster Title: Reduced Brain Atrophy by Gamma Sensory Stimulation in Alzheimer’s Disease Patients

Presenting Author: Mihaly Hajós, Ph.D., et al.

Poster Title: Study Design of Gamma Sensory Stimulation at Multiple Dose Levels in MCI Patients

Presenting Author: Evan Hempel, et al.

Poster Title: Safety, feasibility and adherence of a daily, in-home, sensory stimulation therapy with the Cognito Sensory Stimulation System in Alzheimer’s subjects

Presenting Author: Martin Williams, et al.

Poster Title: Gamma Sensory Stimulation in AD patients, a randomized controlled trial

Presenting Author: Alyssa Boasso, Ph.D., et al.

Poster Title: Maintained Activities of Daily Living and Improved Sleep Quality in Alzheimer’s Patients Receiving Sensory Gamma Stimulation

Presenting Author: Aylin Cimenser, Ph.D., et al.

Poster Title: Effects of Gamma Sensory Stimulation on Cognitive Function in Alzheimer’s Disease Patients

Presenting Author: Aylin Cimenser, Ph.D., et al.

To meet with the Cognito team on-site at AAIC, please contact aaic2021@cognitotx.com.

About Cognito Therapeutics

Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics targeting neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead digital therapeutic reported positive Phase 2 results in Alzheimer’s Disease, and was awarded FDA Breakthrough Device Designation by the FDA. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005344/en/